Skip to menu Skip to content Skip to footer

2020

Journal Article

Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis

Hayward, Kelly L., Valery, Patricia C., Patel, Preya J., Horsfall, Leigh U., Wright, Penny L., Tallis, Caroline J., Stuart, Katherine A., David, Michael, Irvine, Katharine M., Cottrell, W. Neil, Martin, Jennifer H. and Powell, Elizabeth E. (2020). Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis. Internal Medicine Journal, 50 (9), 1142-1146. doi: 10.1111/imj.14986

Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis

2020

Journal Article

Longitudinal change in simple scores identifies fibrosis status in people with nonalcoholic fatty liver disease

McKillen, Benjamin J., Powell, Elizabeth E., Horsfall, Leigh U., Clouston, Andrew D., Brown, Nigel N., Elangovan, Harendran, Patel, Preya J., Valery, Patricia C., Irvine, Katharine M., Bernard, Anne and Hayward, Kelly L. (2020). Longitudinal change in simple scores identifies fibrosis status in people with nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology, 54 (7), 661-662. doi: 10.1097/MCG.0000000000001372

Longitudinal change in simple scores identifies fibrosis status in people with nonalcoholic fatty liver disease

2020

Journal Article

Type 2 diabetes: a risk factor for hospital readmissions and mortality in Australian patients with cirrhosis

Ahn, Sang Bong, Powell, Elizabeth E., Russell, Anthony, Hartel, Gunter, Irvine, Katharine M., Moser, Chris and Valery, Patricia C. (2020). Type 2 diabetes: a risk factor for hospital readmissions and mortality in Australian patients with cirrhosis. Hepatology Communications, 4 (9) hep4.1536, 1279-1292. doi: 10.1002/hep4.1536

Type 2 diabetes: a risk factor for hospital readmissions and mortality in Australian patients with cirrhosis

2020

Journal Article

Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians

Valery, Patricia C., Clark, Paul J., Pratt, Gregory, Bernardes, Christina M., Hartel, Gunter, Toombs, Maree, Irvine, Katharine M. and Powell, Elizabeth E. (2020). Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians. International Journal for Equity in Health, 19 (1) 27, 1-11. doi: 10.1186/s12939-020-1144-6

Hospitalisation for cirrhosis in Australia: disparities in presentation and outcomes for Indigenous Australians

2020

Other Outputs

CSF1R_FRed_SupplementaryVideos

Irvine, Katharine, Hume, David and Sehgal, Anuj (2020). CSF1R_FRed_SupplementaryVideos. The University of Queensland. (Dataset) doi: 10.14264/8c6d4ba

CSF1R_FRed_SupplementaryVideos

2019

Journal Article

Association between the fetal cerebroplacental ratio and biomarkers of hypoxia and angiogenesis in the maternal circulation at term

Irvine, Katharine M., Bligh, Larissa N. and Kumar, Sailesh (2019). Association between the fetal cerebroplacental ratio and biomarkers of hypoxia and angiogenesis in the maternal circulation at term. European Journal of Obstetrics and Gynecology and Reproductive Biology, 245, 198-204. doi: 10.1016/j.ejogrb.2019.11.018

Association between the fetal cerebroplacental ratio and biomarkers of hypoxia and angiogenesis in the maternal circulation at term

2019

Journal Article

Analysis of the impact of CSF‐1 administration in adult rats using a novel Csf1r ‐mApple reporter gene

Irvine, Katharine M., Caruso, Melanie, Cestari, Michelle Ferrari, Davis, Gemma M., Keshvari, Sahar, Sehgal, Anuj, Pridans, Clare and Hume, David A. (2019). Analysis of the impact of CSF‐1 administration in adult rats using a novel Csf1r ‐mApple reporter gene. Journal of Leukocyte Biology, 107 (2) JLB.MA0519-149R, 221-235. doi: 10.1002/jlb.ma0519-149r

Analysis of the impact of CSF‐1 administration in adult rats using a novel Csf1r ‐mApple reporter gene

2019

Journal Article

Clinically significant fibrosis is associated with longitudinal increases in fibrosis-4 and nonalcoholic fatty liver disease fibrosis scores

Janubhai Patel, Preya, Chieh-Yu Cheng, Johnson, Banh, Xuan, Gracen, Lucy, Radford-Smith, Daniel, Hossain, Fabrina, Horsfall, Leigh Ula, Lee Hayward, Kelly, Williams, Suzanne, Johnson, Tracey, Brown, Nigel Neil, Saad, Nivene, Stuart, Katherine Anne, Russell, Anthony William, Valery, Patricia Casarolli, Clouston, Andrew Donald, Irvine, Katharine Margaret, Bernard, Anne and Powell, Elizabeth Ellen (2019). Clinically significant fibrosis is associated with longitudinal increases in fibrosis-4 and nonalcoholic fatty liver disease fibrosis scores. Clinical Gastroenterology and Hepatology, 18 (3), 710-718.e4. doi: 10.1016/j.cgh.2019.07.036

Clinically significant fibrosis is associated with longitudinal increases in fibrosis-4 and nonalcoholic fatty liver disease fibrosis scores

2019

Journal Article

Phenotypic impacts of CSF1R deficiencies in humans and model organisms

Hume, David A., Caruso, Melanie, Ferrari‐Cestari, Michelle, Summers, Kim M., Pridans, Clare and Irvine, Katharine M. (2019). Phenotypic impacts of CSF1R deficiencies in humans and model organisms. Journal of Leukocyte Biology, 107 (2) JLB.MR0519-143R, 205-219. doi: 10.1002/jlb.mr0519-143r

Phenotypic impacts of CSF1R deficiencies in humans and model organisms

2019

Journal Article

Reply

Hayward, Kelly L., Valery, Patricia C., Cottrell, W. Neil, Irvine, Katharine M., Martin, Jennifer H. and Powell, Elizabeth E. (2019). Reply. Hepatology Communications, 3 (9), 1283-1284. doi: 10.1002/hep4.1398

Reply

2019

Journal Article

Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic Type 2 inflammation

Loh, Zhixuan, Fitzsimmons, Rebecca L., Reid, Robert C., Ramnath, Divya, Clouston, Andrew, Gupta, Praveer K., Irvine, Katharine M., Powell, Elizabeth E., Schroder, Kate, Stow, Jennifer L., Sweet, Matthew J., Fairlie, David P. and Iyer, Abishek (2019). Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic Type 2 inflammation. British Journal of Pharmacology, 176 (19) bph.14768, 3775-3790. doi: 10.1111/bph.14768

Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic Type 2 inflammation

2019

Journal Article

Overexpression of miRNA-25-3p inhibits Notch1 signaling and TGF-β-induced collagen expression in hepatic stellate cells

Genz, Berit, Coleman, Miranda A., Irvine, Katharine M., Kutasovic, Jamie R., Miranda, Mariska, Gratte, Francis D., Tirnitz-Parker, Janina E. E., Olynyk, John. K., Calvopina, Diego A., Weis, Anna, Cloonan, Nicole, Robinson, Harley, Hill, Michelle M., Al-Ejeh, Fares and Ramm, Grant A. (2019). Overexpression of miRNA-25-3p inhibits Notch1 signaling and TGF-β-induced collagen expression in hepatic stellate cells. Scientific Reports, 9 (1) 8541, 8541. doi: 10.1038/s41598-019-44865-1

Overexpression of miRNA-25-3p inhibits Notch1 signaling and TGF-β-induced collagen expression in hepatic stellate cells

2019

Conference Publication

Histone Deacetylase Inhibitors Attenuate Hepatic Fibrosis through Suppression of Group 2 Innate Lymphoid Cells and Type 2 Inflammation

Iyer, Abishek, Loh, Zhixuan, Fitzsimmons, Rebecca L., Reid, Robert C., Ramnath, Divya, Clouston, Andrew, Irvine, Katharine M., Powell, Elizabeth E., Schroder, Kate, Stow, Jennifer L., Sweet, Matthew J. and Fairlie, David P. (2019). Histone Deacetylase Inhibitors Attenuate Hepatic Fibrosis through Suppression of Group 2 Innate Lymphoid Cells and Type 2 Inflammation. Experimental Biology Meeting (EB), Orlando Fl, Apr 06-09, 2019. HOBOKEN: WILEY.

Histone Deacetylase Inhibitors Attenuate Hepatic Fibrosis through Suppression of Group 2 Innate Lymphoid Cells and Type 2 Inflammation

2019

Journal Article

Medication‐related problems in outpatients with decompensated cirrhosis: Opportunities for harm prevention

Hayward, Kelly L., Patel, Preya J., Valery, Patricia C., Horsfall, Leigh U., Li, Catherine Y., Wright, Penny L., Tallis, Caroline J., Stuart, Katherine A., Irvine, Katharine M., Cottrell, W. Neil, Martin, Jennifer H. and Powell, Elizabeth E. (2019). Medication‐related problems in outpatients with decompensated cirrhosis: Opportunities for harm prevention. Hepatology Communications, 3 (5) hep4.1334, 620-631. doi: 10.1002/hep4.1334

Medication‐related problems in outpatients with decompensated cirrhosis: Opportunities for harm prevention

2019

Journal Article

Causes and consequences of innate immune dysfunction in cirrhosis

Irvine, Katharine Margaret, Ratnasekera, Isanka, Powell, Elizabeth E. and Hume, David Arthur (2019). Causes and consequences of innate immune dysfunction in cirrhosis. Frontiers in Immunology, 10 (FEB) 293, 293. doi: 10.3389/fimmu.2019.00293

Causes and consequences of innate immune dysfunction in cirrhosis

2019

Journal Article

The mononuclear phagocyte system: the relationship between monocytes and macrophages

Hume, David A., Irvine, Katharine M. and Pridans, Clare (2019). The mononuclear phagocyte system: the relationship between monocytes and macrophages. Trends in Immunology, 40 (2), 98-112. doi: 10.1016/j.it.2018.11.007

The mononuclear phagocyte system: the relationship between monocytes and macrophages

2019

Journal Article

Corrigendum: Causes and consequences of innate immune dysfunction in cirrhosis (Frontiers in Immunology (2019) 10 (293) DOI: 10.3389/fimmu.2019.00293)

Irvine, Katharine Margaret, Ratnasekera, Isanka, Powell, Elizabeth E. and Hume, David Arthur (2019). Corrigendum: Causes and consequences of innate immune dysfunction in cirrhosis (Frontiers in Immunology (2019) 10 (293) DOI: 10.3389/fimmu.2019.00293). Frontiers in Immunology, 10 (APR) 818, 818. doi: 10.3389/fimmu.2019.00818

Corrigendum: Causes and consequences of innate immune dysfunction in cirrhosis (Frontiers in Immunology (2019) 10 (293) DOI: 10.3389/fimmu.2019.00293)

2018

Journal Article

ADGRE1 (EMR1, F4/80) is a rapidly-evolving gene expressed in mammalian monocyte-macrophages

Waddell, Lindsey A., Lefevre, Lucas, Bush, Stephen J., Raper, Anna, Young, Rachel, Lisowski, Zofia M., McCulloch, Mary E.B., Muriuki, Charity, Sauter, Kristin A., Clark, Emily L., Irvine, Katharine M., Pridans, Clare, Hope, Jayne C. and Hume, David A. (2018). ADGRE1 (EMR1, F4/80) is a rapidly-evolving gene expressed in mammalian monocyte-macrophages. Frontiers in Immunology, 9 (OCT) 2246. doi: 10.3389/fimmu.2018.02246

ADGRE1 (EMR1, F4/80) is a rapidly-evolving gene expressed in mammalian monocyte-macrophages

2018

Conference Publication

Macrophage colony stimulating factor (CSF1) promotes regression of advanced fibrosis and liver regeneration in mice

Irvine, Katharine, Genz, Berit, Clouston, Andrew D. and Hume, David (2018). Macrophage colony stimulating factor (CSF1) promotes regression of advanced fibrosis and liver regeneration in mice. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, CA USA, 9-13 November 2018. Hoboken, NJ USA: Wiley.

Macrophage colony stimulating factor (CSF1) promotes regression of advanced fibrosis and liver regeneration in mice

2018

Journal Article

A pragmatic approach identifies a high rate of nonalcoholic fatty liver disease with advanced fibrosis in diabetes clinics and at-risk populations in primary care

Patel, Preya Janubhai, Hossain, Fabrina, Horsfall, Leigh Ula, Banh, Xuan, Hayward, Kelly Lee, Williams, Suzanne, Johnson, Tracey, Bernard, Anne, Brown, Nigel Neil, Lampe, Guy, Buck, Lyndall, Saad, Nivene, Russell, Anthony William, Valery, Patricia Casarolli, Irvine, Katharine Margaret, Clouston, Andrew Donald, Stuart, Katherine Anne, Rosenberg, William and Powell, Elizabeth Ellen (2018). A pragmatic approach identifies a high rate of nonalcoholic fatty liver disease with advanced fibrosis in diabetes clinics and at-risk populations in primary care. Hepatology Communications, 2 (8), 893-905. doi: 10.1002/hep4.1208

A pragmatic approach identifies a high rate of nonalcoholic fatty liver disease with advanced fibrosis in diabetes clinics and at-risk populations in primary care